Abstract
Dissolving microneedle (DMN) is referred to a microscale needle that encapsulates drug(s) within a biodegradable polymer matrix and delivers it into the skin in a minimally invasive manner. Although vast majority of studies have emphasized DMN as an efficient drug delivery system, the activity of DMN-encapsulated proteins or antigens can be significantly affected due to a series of thermal, physical and chemical stress factors during DMN fabrication process and storage period. The objective of this study is to evaluate the effects of DMN fabrication parameters including polymer type, polymer concentration, fabrication and storage temperature, and drying conditions on the activity of the encapsulated therapeutic proteins by employing lysozyme (LYS) as a model protein. Our results indicate that a combination of low temperature fabrication, mild drying condition, specific polymer concentration, and addition of protein stabilizer can maintain the activity of encapsulated LYS up to 99.8 ± 3.8%. Overall, findings of this study highlight the importance of optimizing DMN fabrication parameters and paves way for the commercialization of an efficient delivery system for therapeutics.
| Original language | English |
|---|---|
| Pages (from-to) | 290-296 |
| Number of pages | 7 |
| Journal | European Journal of Pharmaceutical Sciences |
| Volume | 117 |
| DOIs | |
| Publication status | Published - 2018 May 30 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
Cite this
}
Effects of dissolving microneedle fabrication parameters on the activity of encapsulated lysozyme. / Fakhraei Lahiji, Shayan; Jang, Yoojung; Ma, Yonghao; Dangol, Manita; Yang, Huisuk; Jang, Mingyu; Jung, Hyungil.
In: European Journal of Pharmaceutical Sciences, Vol. 117, 30.05.2018, p. 290-296.Research output: Contribution to journal › Article
TY - JOUR
T1 - Effects of dissolving microneedle fabrication parameters on the activity of encapsulated lysozyme
AU - Fakhraei Lahiji, Shayan
AU - Jang, Yoojung
AU - Ma, Yonghao
AU - Dangol, Manita
AU - Yang, Huisuk
AU - Jang, Mingyu
AU - Jung, Hyungil
PY - 2018/5/30
Y1 - 2018/5/30
N2 - Dissolving microneedle (DMN) is referred to a microscale needle that encapsulates drug(s) within a biodegradable polymer matrix and delivers it into the skin in a minimally invasive manner. Although vast majority of studies have emphasized DMN as an efficient drug delivery system, the activity of DMN-encapsulated proteins or antigens can be significantly affected due to a series of thermal, physical and chemical stress factors during DMN fabrication process and storage period. The objective of this study is to evaluate the effects of DMN fabrication parameters including polymer type, polymer concentration, fabrication and storage temperature, and drying conditions on the activity of the encapsulated therapeutic proteins by employing lysozyme (LYS) as a model protein. Our results indicate that a combination of low temperature fabrication, mild drying condition, specific polymer concentration, and addition of protein stabilizer can maintain the activity of encapsulated LYS up to 99.8 ± 3.8%. Overall, findings of this study highlight the importance of optimizing DMN fabrication parameters and paves way for the commercialization of an efficient delivery system for therapeutics.
AB - Dissolving microneedle (DMN) is referred to a microscale needle that encapsulates drug(s) within a biodegradable polymer matrix and delivers it into the skin in a minimally invasive manner. Although vast majority of studies have emphasized DMN as an efficient drug delivery system, the activity of DMN-encapsulated proteins or antigens can be significantly affected due to a series of thermal, physical and chemical stress factors during DMN fabrication process and storage period. The objective of this study is to evaluate the effects of DMN fabrication parameters including polymer type, polymer concentration, fabrication and storage temperature, and drying conditions on the activity of the encapsulated therapeutic proteins by employing lysozyme (LYS) as a model protein. Our results indicate that a combination of low temperature fabrication, mild drying condition, specific polymer concentration, and addition of protein stabilizer can maintain the activity of encapsulated LYS up to 99.8 ± 3.8%. Overall, findings of this study highlight the importance of optimizing DMN fabrication parameters and paves way for the commercialization of an efficient delivery system for therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85042916090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042916090&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2018.03.003
DO - 10.1016/j.ejps.2018.03.003
M3 - Article
VL - 117
SP - 290
EP - 296
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
SN - 0928-0987
ER -